Search

Your search keyword '"Sharpe C"' showing total 594 results

Search Constraints

Start Over You searched for: Author "Sharpe C" Remove constraint Author: "Sharpe C"
594 results on '"Sharpe C"'

Search Results

2. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

3. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

4. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

5. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

6. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

8. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

10. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

11. Revival of the magnetar PSR J1622-4950: observations with MeerKAT, Parkes, XMM-Newton, Swift, Chandra, and NuSTAR

12. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

13. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

14. Pragmatic clinico-pathological sub-classification of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) with multicentre validation

15. Long COVID research: an update from the PHOSP-COVID Scientific Summit

19. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

20. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

21. Verification of Inference Observability in Supervisory Control of Discrete-Event Systems

22. Severity of COVID-19 after Vaccination among Hemodialysis Patients: An Observational Cohort Study

23. Multicentre real world long-term outcomes in 2773 primary Non-Muscle Invasive Bladder Cancer (NMIBC) patients managed within the Scottish Bladder Cancer Quality Performance Indicator programme

24. Ceasing surveillance in low risk non-muscle invasive bladder cancer after only 12 months of being recurrence free is un-safe: A validation study from the Scottish bladder cancer Quality Performance Indicator (QPI) programme

27. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

30. Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence

34. POS-513 RISK OF COVID-19 DISEASE, DIALYSIS UNIT ATTRIBUTES AND INFECTION CONTROL STRATEGY AMONG LONDON IN-CENTRE HAEMODIALYSIS PATIENTS: A RETROSPECTIVE COHORT STUDY

35. POS-029 PATTERNS OF AKI IN PATIENTS HOSPITALISED WITH COVID-19 DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC IN A LARGE UK TERTIARY CENTRE

36. Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

46. Variation in protein coding genes identifies information flow as a contributor to animal complexity

49. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial.

Catalog

Books, media, physical & digital resources